Clinical Trials
12 trialsNCT00878163 2026-04-13
GDC-0449 and Erlotinib Hydrochloride With or Without Gemcitabine Hydrochloride in Treating Patients With Metastatic Pancreatic Cancer or Solid Tumors That Cannot Be Removed by Surgery
National Cancer Institute (NCI)
Phase 1 Active not recruiting
NCT06616623 2026-02-27
Vismodegib and Atezolizumab for the Treatment of Recurrent or Metastatic Non-Small Cell Lung Cancer
Ohio State University Comprehensive Cancer Center
Phase 1 Recruiting
NCT03878524 2024-03-04
Serial Measurements of Molecular and Architectural Responses to Therapy (SMMART) PRIME Trial
OHSU Knight Cancer Institute
Phase 1 Terminated
NCT01537107 2019-04-08
Sirolimus and Vismodegib in Treating Patients With Solid Tumors or Pancreatic Cancer That is Metastatic or Cannot Be Removed By Surgery
Mayo Clinic
Phase 1 Completed
NCT02639117 2018-07-18
PDT-Vismo
University of Arizona
Phase 1 Completed
NCT00968981 2017-07-11
A Study of Hedgehog Pathway Inhibitor GDC-0449 in Patients With Locally Advanced or Metastatic Solid Tumors That Are Refractory to Standard Therapy or for Whom No Standard Therapy Exists
Genentech, Inc.
Phase 1 Completed
NCT01546519 2016-05-23
A Study of Vismodegib in Patients With Advanced Solid Malignancies Including Hepatocellular Carcinoma With Varying Degrees of Renal or Hepatic Function
Genentech, Inc.
Phase 1 Completed
NCT00607724 2015-10-08
GDC-0449 in Treating Patients With Locally Advanced or Metastatic Solid Tumors
Genentech, Inc.
Phase 1 Completed
NCT01209143 2015-06-29
A Study of Pharmacokinetic Drug Interaction Study of the Hedgehog Pathway Inhibitor GDC-0449 in Combination With Rosiglitazone or Combined Oral Contraceptive in Patients With Locally Advanced or Metastatic Solid Tumors That Are Refractory to Standard Therapy or for Whom No Standard Therapy Exists
Genentech, Inc.
Phase 1 Completed
NCT01071564 2015-04-15
RO4929097 and Vismodegib in Treating Patients With Breast Cancer That is Metastatic or Cannot Be Removed By Surgery
National Cancer Institute (NCI)
Phase 1 Terminated
NCT01330173 2014-12-23
Vismodegib After Stem Cell Transplant in Treating Patients With High-Risk First Remission or Relapsed Multiple Myeloma
National Cancer Institute (NCI)
Phase 1 Completed
NCT00822458 2014-04-02
GDC-0449 in Treating Young Patients With Medulloblastoma That is Recurrent or Did Not Respond to Previous Treatment
National Cancer Institute (NCI)
Phase 1 Completed